This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.00% per year. These returns cover a period from January 1, 1988 through May 4, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
How AbbVie's Pipeline Is Lining Up Key Product Launches
by Sundeep Ganoria
ABBV is lining up multiple late-stage launches, from Rinvoq label expansions to Parkinson???s and oncology assets nearing FDA decisions.
biotechs medical pharmaceuticals
GILD's Bictegravir and Lenacapavir Regimen for HIV Meets Primary Goal
by Zacks Equity Research
Gilead said its once-daily bictegravir/lenacapavir tablet met non-inferiority vs Biktarvy in phase III ARTISTRY-2, paving the way for filings.
biotechnology biotechs medical pharmaceuticals
FDA Approves J&J's Akeega for Expanded Use in Prostate Cancer
by Zacks Equity Research
JNJ secures FDA approval to expand Akeega into earlier-stage prostate cancer, backed by strong phase III data and a first-of-its-kind precision combo.
biotechs medical
CHMP Backs Higher-Dose Wegovy as Novo Nordisk Seeks 2026 EU Approval
by Zacks Equity Research
NVO gains CHMP backing for a higher-dose Wegovy, paving the way for potential EU approval in 2026 as study data show stronger weight loss.
biotechnology biotechs medical pharmaceuticals
GSK's Nucala for COPD and Depemokimab for Asthma Get CHMP Nod in EU
by Zacks Equity Research
GSK gets CHMP backing for Nucala in COPD and depemokimab in asthma, setting up possible Europe approvals in 2026 for IL-5 therapies.
biotechs medical
RCUS Stock Down on Decision to Discontinue GILD Partnered Study
by Zacks Equity Research
Arcus halts the late-stage STAR-221 study for futility, dealing a setback to its domvanalimab program with Gilead. Stock down.
biotechnology biotechs medical pharmaceuticals
BMY Gains 13.1% in Three Months: Buy, Sell or Hold the Stock?
by Ekta Bagri
BMY shares are rebounding after a strong Q3, lifted by rising demand for Opdivo, Reblozyl and Camzyos, even as legacy drugs face generic pressure.
biotechs medical pharmaceuticals
Eli Lilly's Next-Generation Obesity Drug Secures First Phase III Win
by Zacks Equity Research
LLY's retatrutide posts strong weight-loss and pain-reduction results in its first Phase III study, boosting investor optimism.
biotechs medical pharmaceuticals
NVO Down 42% Year to Date: Is This an Indication to Sell the Stock?
by Ahan Chakraborty
Novo Nordisk stock plunges 42% so far in 2025 as GLP-1 competition, price cuts, guidance trims and restructuring plans cloud growth and elevate execution risks.
biotechnology biotechs medical pharmaceuticals
Can Opdivo's Label Expansions Help Bristol Myers Sustain Its Momentum?
by Zacks Equity Research
BMY gets a priority FDA review for Opdivo's use in previously untreated advanced Hodgkin lymphoma, reinforcing its oncology momentum.
biotechnology biotechs medical pharmaceuticals